BioSpace News Archive

Lokavant, the clinical trial intelligence platform company, announces the launch of a study planning solution driven by proprietary historical trial data from more than 2,000 studies involving more than 14,000 investigators, 12,000 healthcare institutions, and real-world data (RWD) sources.

Morphic Therapeutic announced that Marc Schegerin, MD, COO & CFO, will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, September 6th at 8:00 AM ET.

ImmuCell Corporation announced that it recently submitted the Chemistry, Manufacturing and Controls Technical Section for Re-Tain® to the FDA.

Akeso Inc. (“Akeso”, 9926. HK) announced completion of patient enrollment in a head-to-head study of ivonescimab (AK112, PD-1/VEGF bispecific antibody) compared with pembrolizumab as first-line treatment for patients with PD-L1 positive (PD-L1 TPS≥1%) locally advanced or metastatic non-small cell lung cancer (NSCLC).

ICU Medical Inc., a worldwide leader in the development, manufacture and sale of innovative medical devices, today announced that the company has received 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA) for the Plum Duo infusion pump with LifeShield infusion safety software.

Day Zero Diagnostics Inc., a pioneer in infectious disease diagnostics, has received a Phase I Small Business Innovation Research award from the National Institute of Allergies and Infectious Disease of the National Institutes of Health.

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO will present at the H.C. Wainwright 25th Annual Global Investment Conference.

Mycobacterium tuberculosis (Mtb) is the pathogen that causes tuberculosis (TB), the world’s deadliest infectious disease.

Scale Biosciences, Inc. (ScaleBio™), an innovator in single cell sequencing leveraging combinatorial indexing technologies, today announced an expansion of their product portfolio to enable a broader range of single cell omics experiments and unlock new translational research applications.

Aldevron contributed to a publication in collaboration with 2020 Nobel Laureate Jennifer Doudna and the Innovative Genomics Institute (IGI) at the University of California, Berkeley to advance research on in vivo, CRISPR-based genome editing strategies to address genetic diseases of the central nervous system such as Huntington’s disease and ALS.